Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients

Rheumatology International

Volumn 32, Issue 9, 2012, Pages 2833-2836

  Mohammadzadeh, Adel ^a   Pourfathollah, Ali Akbar ^a   Tahoori, Mohammad Taher ^a   Daneshmandi, Saeed ^a   Langroudi, Ladan ^a   Akhlaghi, Masoumeh ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Fas; FasL; Iranian patient; Rheumatoid arthritis; SNP

Indexed keywords

ALANINE; CYSTEINE; FAS ANTIGEN; FAS LIGAND; GLYCINE; THREONINE;

ADULT; ALLELE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, CD95; APOPTOSIS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IRAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84866347165     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2065-x     Document Type: Article

References (25)

1. Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:527-535 (Pubitemid 37328744)
2. Hasunuma T, Kayagaki N, Asahara H et al (1997) Accumulation of soluble Fas in inflamed joints of patient with rheumatoid arthritis. Arthritis Reum 40:80-86 (Pubitemid 27044039)
3. Asahara H, Hasunuma T, Kubata T et al (1997) In situ expression of protooncogenes and Fas/Fas ligand in rheumatoid arthritis synovium. J Rheumatol 24:430-435 (Pubitemid 27153403)
4. Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ (1997) Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 40:1644-1652 (Pubitemid 27426158)
5. Perlman H, Pagliari LJ, Liu H, Koch AE, Haines GK III, Pope RM (2001) Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum 44:21-30 (Pubitemid 32113114)
6. Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L (2002) Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 61:934-936
7. Schedel J, Gay RE, Kuenzler P et al (2002) FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum 46:1512-1518 (Pubitemid 34620197)
8. Zhang J, Bardos T, Mikecz K, Finnegan A, Glant TT (2001) Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J Immunol 166:4981-4986 (Pubitemid 32280709)
9. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178 (Pubitemid 24006113)
10. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327-4330 (Pubitemid 36950998)
11. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170:132-138 (Pubitemid 36026132)
12. Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R (2000) Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome. J Rheumatol 27:2397-2405
13. Besma BHJ, Wijden M, Noureddine B, Sallouha G, Slim BA et al (2006) A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 233:21-27
14. Stuck BJ, Pani MA, Besrour F et al (2003) Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease. Hum Immunol 64:285-289 (Pubitemid 36197357)
15. Ogawa Y, Kuwahara H, Kimura T et al (2001) Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. J Rheumatol 28:950-955 (Pubitemid 32422572)
16. Guery L, Batteux F, Bessis N et al (2000) Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis. Eur J Immunol 30:308-315 (Pubitemid 30011793)
17. Kim SH, Kim S, Oligino TJ, Robbins PD (2002) Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 6:584-590 (Pubitemid 35363690)
18. Catrina AI, Trollmo C, af Klint E et al (2005) Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61-72 (Pubitemid 40129233)
19. Cohen PL, Eisenberg RA (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243-269
20. Das H, Koizumi T, Sugimoto T et al (2000) Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 82:1682-1688 (Pubitemid 30229579)
21. Kanemitsu S et al (2002) A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29:1183-1188 (Pubitemid 34601951)
22. Huang QR et al (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577-582 (Pubitemid 27512871)
23. Huang WX, Huang MP, Gomes MA, Hillert J (2000) Apoptosis mediator's fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55:928-934
24. Krammer PH (2000) CD95's deadly mission in the immune system. Nature 407:789-795
25. Shimonishi T, Isse K, Shibata F et al (2000) Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32:761-769